
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a promising biotechnology company specializing in the development of innovative treatments for inflammatory and immune-mediated diseases, with a strong focus on developing a potentially first-in-class DR3 antagonist antibody for the treatment of IBD. With a well-established expertise in protein engineering, the company's lead asset SL-325 has shown impressive efficacy and safety signals in preclinical and clinical studies, positioning it as a potential best-in-class drug. Additionally, the company's diverse pipeline, including the recently disclosed bispecific candidate SL-846, presents significant potential for future growth. While risks exist, including the competitive landscape and financing requirements, we maintain a positive outlook on Shattuck Labs based on its promising pipeline, strong management team, and solid financial position, with operational runway through 2029.
Bears say
Shattuck Labs is currently developing potential treatments for inflammatory and immune-mediated diseases, including a first-in-class antibody for the treatment of inflammatory bowel disease. Despite promising data from a Phase 1 clinical trial, there are concerns regarding competition from other companies targeting the same pathway and the potential for the company's preclinical assets to successfully progress into clinical studies. Additionally, the company's valuation is based on a 6x multiple to estimated sales in 2035-2037, which is highly dependent on the future success of its drugs. These factors contribute to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares